Abstracts tagged "adalimumab and economics"

Abstract Number: 1047 • 2017 ACR/ARHP Annual Meeting
Cost-Effectiveness of Drug-Level Guided Adalimumab Dosing
Zara Izadi¹, Gabriela Schmajuk², Milena Gianfrancesco³, Laura Trupin⁴, Kashif Jafri⁵, Jinoos Yazdany⁴ and Dhruv Kazi⁶, ¹Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Department of Medicine, University of California, San Francisco, Zuckerberg San Francisco General Hospital, San Francisco, CA
Background/Purpose: Adalimumab (ADA) induces and maintains clinical remission in patients with rheumatoid arthritis (RA) and Crohn’s disease (CD) but is an expensive drug. Drug-level and…
Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Malte Wolff¹, Zheng-Yi Zhou², James Signorovitch², James W. Shaw³ and Arijit Ganguli³, ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.